Download PDF
Exp Clin Endocrinol Diabetes 2002; 110(5): 230-234
DOI: 10.1055/s-2002-33072
Articles

© Johann Ambrosius Barth

The Pro115Gln polymorphism within the PPAR γ2 gene has no epidemiological impact on morbid obesity

O. W. Hamer1 , D. Forstner1 , I. Ottinger1 , M. Ristow2 , L. C. Bollheimer1 , J. Schölmerich1 , K. D. Palitzsch1
  • 1 Department of Internal Medicine I, University of Regensburg, Germany
  • 2 German Institute for Nutrition, DIFE, KLE, C2, Bergholz-Potsdam, Germany
Further Information

Publication History

received 27 February 2001 first decision 26 April 2001

accepted 13 February 2002

Publication Date:
30 July 2002 (online)

Also available at
    Permissions and Reprints

Summary

The peroxisome-proliferator-activated receptor γ2 (PPAR γ2) is a transcriptional key regulator of adipocyte differentiation. PPARγ2 can be inactivated by phosphorylation of a serine residue at position 114. A point mutation leading to an amino acid exchange at position 115 (Pro115Gln) was shown to preclude serine phosphorylation and to consecutively accelerate adipocyte differentiation emphasizing the pathophysiological relevance of this mutation.

So far, four markedly obese heterozygote carriers of the Pro115Gln mutation (body mass index 37.9-47.3 kg×m-2) have been identified in a circumscribed study population. In order to evaluate the epidemiological relevance of the Pro115Gln mutation in morbid obesity we screened the DNA of all subjects with a body mass index greater than 35 kg×m-2 who had participated in a nationwide German epidemiological field survey. There was no homozygote or heterozygote carrier of the Pro115Gln polymorphism among them. We conclude that the Pro115Gln polymorphism within the PPAR γ2 gene has no relevant epidemiological impact on morbid obesity in Germany. It needs further investigation whether this polymorphism might play a role in related metabolic disorders.

Key words:

Peroxisome-proliferator-activated receptor γ2 - Pro115Gln - Obesity - Polymorphism - Epidemiology

References

  • 1 Adams M, Reginato M J, Shao D, Lazar M A, Chatterjee V K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site.  J Biol Chem. 1997;  272 5125-5132
    PubMedGoogle Scholar
  • 2 Auboeuf D, Rieusset J, Fajas L, Vallier P, Riou J P, Staels B, Auwerx J, Laville M, Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients.  Diabets. 1997;  46 1319-1327
    PubMedGoogle Scholar
  • 3 Auwerx J. PPARgamma, the ultimate thrifty gene.  Diabetologia. 1999;  42 1033-1049
    CrossrefPubMedGoogle Scholar
  • 4 Bouchard C. Genetics of obesity in humans: current issues.  Ciba Found Symp. 1996;  201 108-115
    PubMedGoogle Scholar
  • 5 Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.  Endocrinology. 1996;  137 354-366
    CrossrefPubMedGoogle Scholar
  • 6 Clement K, Hercberg S, Passinge B, Galan P, Barroud-Vial M, Shuldiner A R, Beamer B A, Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes.  Int J Obes Relat Metab Disord. 2000;  24 391-393
    CrossrefPubMedGoogle Scholar
  • 7 Day C. Thiazolidinediones: a new class of antidiabetic drugs.  Diabet Med. 1999;  16 179-192
    CrossrefPubMedGoogle Scholar
  • 8 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism.  Endocr Rev. 1999;  20 649-688
    CrossrefPubMedGoogle Scholar
  • 9 Evans D, Mann W A, Heer J, Michel U, Wendt D, Kortner B, Wolf A, Beisiegel U. Variation in the gene for human peroxisome proliferator activated receptor gamma (PPARgamma) does not play a major role in the development of morbid obesity.  Int J Obes Relat Metab Disord. 2000;  24 647-651
    PubMedGoogle Scholar
  • 10 Fajas L, Fruchart J C, Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.  FEBS Lett. 1998;  438 55-60
    CrossrefPubMedGoogle Scholar
  • 11 Greene M E, Blumberg B, McBride O W, Yi H F, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer S D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.  Gene Expr. 1995;  4 281-299
    PubMedGoogle Scholar
  • 12 Hamann A, Munzberg H, Buttron P, Busing B, Hinney A, Mayer H, Siegfried W, Hebebrand J, Greten H. Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects.  Eur J Endocrinol. 1999;  141 90-92
    CrossrefPubMedGoogle Scholar
  • 13 Hu E, Kim J B, Sarraf P, Spiegelman B M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.  Science. 1996;  274 2100-2103
    CrossrefPubMedGoogle Scholar
  • 14 Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, Saruta T. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.  Metabolism. 1999;  48 1102-1107
    CrossrefPubMedGoogle Scholar
  • 15 Kliewer S A, Forman B M, Blumberg B, Ong E S, Borgmeyer U, Mangelsdorf D J, Umesono K, Evans R M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.  Proc Natl Acad Sci U S A. 1994;  91 7355-7359
    PubMedGoogle Scholar
  • 16 Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.  Biochimie. 1997;  79 81-94
    CrossrefPubMedGoogle Scholar
  • 17 Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D. Evolution of the nuclear receptor gene superfamily.  EMBO J. 1992;  11 1003-1013
    PubMedGoogle Scholar
  • 18 Maes H H, Neale M C, Eaves L J. Genetic and environmental factors in relative body weight and human adiposity.  Behav Genet. 1997;  27 325-351
    CrossrefPubMedGoogle Scholar
  • 19 Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients.  Diabetes Care. 1999;  22 908-912
    CrossrefPubMedGoogle Scholar
  • 20 Palitzsch K D, Nusser J, Arndt H, Enger I, Zietz B, Cuk A, Schaeffler A, Büttner R, Frick E, Rath H, Schölmerich J. Diabetomobil Study Group . Die Praevalenz des Diabetes mellitus wird in Deutschland deutlich unterschätzt - eine bundesweite epidemiologische Studie auf der Basis einer HbA1c - Analyse.  Diab Stoffw. 1999;  8 189-200
    PubMedGoogle Scholar
  • 21 Perusse L, Chagnon Y C, Bouchard C. Etiology of massive obesity: role of genetic factors.  World J Surg. 1998;  22 907-912
    CrossrefPubMedGoogle Scholar
  • 22 Riddle M C. Learning to use troglitazone.  Diabetes Care. 1998;  21 1389-1390
    PubMedGoogle Scholar
  • 23 Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn C R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation.  N Engl J Med. 1998;  339 953-959
    CrossrefPubMedGoogle Scholar
  • 24 Scheen A J, Lefebvre P J. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.  Diabetes Care. 1999;  22 1568-1577
    PubMedGoogle Scholar
  • 25 Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.  J Lipid Res. 1996;  37 907-925
    PubMedGoogle Scholar
  • 26 Sorensen T I. The genetics of obesity.  Metabolism. 1995;  44 4-6
    PubMedGoogle Scholar
  • 27 Spiegelman B M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.  Diabetes. 1998;  47 507-514
    CrossrefPubMedGoogle Scholar
  • 28 Spiegelman B M, Flier J S. Adipogenesis and obesity: rounding out the big picture.  Cell. 1996;  87 377-389
    CrossrefPubMedGoogle Scholar
  • 29 Tontonoz P, Hu E, Spiegelman B M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid- activated transcription factor.  Cell. 1994;  79 1147-1156
    CrossrefPubMedGoogle Scholar
  • 30 Vidal-Puig A J, Considine R V, Jimenez-Linan M, Werman A, Pories W J, Caro J F, Flier J S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.  J Clin Invest. 1997;  99 2416-2422
    CrossrefPubMedGoogle Scholar
  • 31 Zhang B, Berger J, Hu E, Szalkowski D, White-Carrington S, Spiegelman B M, Moller D E. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha.  Mol Endocrinol. 1996;  10 1457-1466
    CrossrefPubMedGoogle Scholar
  • 32 Zhu Y, Qi C, Korenberg J R, Chen X N, Noya D, Rao M S, Reddy J K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms.  Proc Natl Acad Sci USA. 1995;  92 7921-7925
    PubMedGoogle Scholar

Dr. O. Hamer

Klinik und Poliklinik für Innere Medizin I

Universitätsklinik Regensburg

93042 Regensburg

Germany

Phone: +49- 941-944 7001

Fax: +49- 941-944 7002

Email: okka.hamer@klinik.uni-regensburg.de